Feed/Companies/BrainChild Bio

BrainChild Bio

As of 14 Oct 2026, BrainChild Bio has raised $116M across 1 verified round on record; latest: $116 million Series A, announced 8 Sep 2026.

BrainChild Bio develops CAR T cell therapies focused on treating pediatric and adult brain tumors.

brainchildbio.comLinkedInSEATTLE and CAMBRIDGE, Mass.

LATEST ROUND

Series A

$116M · 2026-09-08

RAISED ON RECORD · USD

$116M

across 1 verified round

INVESTORS

no lead named

SOURCES

from 1 publisher

Company

Every round on record, with the sources behind each and the investors on them.

Series A

$116M · 2026-09-08

[ HISTORY ]

lead not stated

Round	Amount	Announced	Lead	Buzz
Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$116M	2026-09-08	not stated	No recent discussion
1 source [ VERIFIED ] read against 1 source